NASDAQ:NBIX Neurocrine Biosciences - NBIX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $108.38 -0.42 (-0.39%) (As of 01/26/2023 04:30 PM ET) Add Compare Share Share Today's Range$107.61▼$109.5150-Day Range$107.99▼$127.0652-Week Range$72.28▼$129.29Volume695,731 shsAverage Volume892,943 shsMarket Capitalization$10.42 billionP/E Ratio190.14Dividend YieldN/APrice Target$122.24 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside13.3% Upside$122.24 Price TargetShort InterestHealthy2.75% of Float Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.42Based on 26 Articles This WeekInsider TradingSelling Shares$17.06 M Sold Last QuarterProj. Earnings Growth107.18%From $1.81 to $3.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector198th out of 1,048 stocksBiological Products, Except Diagnostic Industry31st out of 168 stocks 3.3 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 9 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $122.24, Neurocrine Biosciences has a forecasted upside of 13.3% from its current price of $107.88.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.75% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 15.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 2.5 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Neurocrine Biosciences this week, compared to 4 articles on an average week.Search Interest9 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,059,059.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.58% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 107.18% in the coming year, from $1.81 to $3.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 189.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 128.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 189.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 95.14.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 7.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.Read More Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock News HeadlinesJanuary 25, 2023 | marketbeat.comPliant Therapeutics Gaps 34% Higher: More Upside To Come? (NBIX)Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.January 25, 2023 | seekingalpha.comNeurocrine Biosciences: Stencil In These Important DatesJanuary 26, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 25, 2023 | americanbankingnews.comQ4 2022 EPS Estimates for Neurocrine Biosciences, Inc. Decreased by Wedbush (NASDAQ:NBIX)January 25, 2023 | americanbankingnews.comSVB Leerink Brokers Increase Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)January 24, 2023 | americanbankingnews.comSVB Leerink Weighs in on Neurocrine Biosciences, Inc.'s Q4 2022 Earnings (NASDAQ:NBIX)January 24, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Neurocrine Biosciences, Inc.'s FY2022 Earnings (NASDAQ:NBIX)January 24, 2023 | seekingalpha.comNBIX Neurocrine Biosciences, Inc.January 26, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 24, 2023 | americanbankingnews.comBrokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Target Price at $122.24January 17, 2023 | finance.yahoo.comNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial ResultsJanuary 12, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Neurocrine (NBIX)January 11, 2023 | nasdaq.comNeurocrine, Voyager To Advance Multiple Gene Therapies For Neurological Diseases TreatmentJanuary 9, 2023 | bloomberg.comVoyager Could Get Up to $4.4 Billion in Neurocrine PartnershipJanuary 9, 2023 | bloomberg.comVoyager to Get as Much as $1.7 Billion in Neurocrine PartnershipJanuary 9, 2023 | finance.yahoo.comVoyager, Neurocrine sign new deal worth up to $4.2BJanuary 9, 2023 | msn.comVoyager jumps 29% on licensing deal with NeurocrineJanuary 6, 2023 | finance.yahoo.comDow Jones Rallies On December Jobs Report; Tesla Stock Dives To New Low On China Price CutsJanuary 3, 2023 | finance.yahoo.comNeurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 28, 2022 | finance.yahoo.comDow Jones Futures Rise Ahead Of Economic Data; Tesla Stock Set To Rebound Amid Historic PlungeDecember 27, 2022 | finance.yahoo.comDow Jones Futures Rise Ahead Of Housing Data; Tesla Plunges On Reduced Production ScheduleDecember 23, 2022 | finance.yahoo.comDow Jones Futures Reverse Lower On Inflation Data; Tesla Stock Rallies On Elon Musk CommentsDecember 22, 2022 | finance.yahoo.comNeurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington DiseaseDecember 17, 2022 | finance.yahoo.comDow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market RallyDecember 10, 2022 | finance.yahoo.comNeurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?December 7, 2022 | markets.businessinsider.comMizuho Securities Keeps Their Hold Rating on Neurocrine (NBIX)December 6, 2022 | finance.yahoo.comNeurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During SleepSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Company Calendar Last Earnings11/01/2022Today1/26/2023Next Earnings (Confirmed)2/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$122.24 High Stock Price Forecast$150.00 Low Stock Price Forecast$94.00 Forecasted Upside/Downside+12.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$0.57 Trailing P/E Ratio190.14 Forward P/E Ratio59.88 P/E GrowthN/ANet Income$89.60 million Net Margins4.19% Pretax Margin5.92% Return on Equity4.06% Return on Assets2.78% Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.41 Sales & Book Value Annual Sales$1.13 billion Price / Sales9.19 Cash Flow$1.24 per share Price / Cash Flow87.51 Book Value$14.48 per share Price / Book7.48Miscellaneous Outstanding Shares96,134,000Free Float91,904,000Market Cap$10.42 billion OptionableOptionable Beta0.54 Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 65)CEO & Director Comp: $1.58MMr. Matthew C. Abernethy (Age 43)Chief Financial Officer Comp: $906.76kDr. Jude Onyia Ph.D. (Age 59)Chief Scientific Officer Comp: $621.66kMr. Eric S. Benevich (Age 58)Chief Commercial Officer Comp: $805kDr. Eiry Wyn Roberts M.D. (Age 59)Chief Medical Officer Comp: $925.46kDr. Dimitri E. Grigoriadis (Age 65)Chief Research Officer Jane SorensenHead of Investor RelationsMr. Darin M. Lippoldt (Age 57)Chief Legal Officer & Corp. Sec. Mr. Kyle W. Gano (Age 50)Chief Bus. Devel. and Strategy Officer Ms. Julie S. Cooke (Age 57)Chief HR Officer More ExecutivesKey CompetitorsRepligenNASDAQ:RGENHalozyme TherapeuticsNASDAQ:HALOExelixisNASDAQ:EXELSeagenNASDAQ:SGENQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsStrs OhioBought 3,047 shares on 1/26/2023Ownership: 0.017%Baker Tilly Wealth Management LLCSold 1,118 shares on 1/26/2023Ownership: 0.004%Tokio Marine Asset Management Co. Ltd.Bought 1,297 shares on 1/26/2023Ownership: 0.004%YorkBridge Wealth Partners LLCSold 765 shares on 1/26/2023Ownership: 0.003%Dupont Capital Management CorpSold 435 shares on 1/26/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NBIX Stock - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price forecast for 2023? 16 brokerages have issued 1 year target prices for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $94.00 to $150.00. On average, they predict the company's share price to reach $122.24 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2023? Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX stock has decreased by 8.9% and is now trading at $108.80. View the best growth stocks for 2023 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023. View our NBIX earnings forecast. How can I listen to Neurocrine Biosciences' earnings call? Neurocrine Biosciences will be holding an earnings conference call on Monday, February 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Tuesday, November, 1st. The company reported $0.69 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by $0.15. The company earned $387.90 million during the quarter, compared to analysts' expectations of $378.05 million. Neurocrine Biosciences had a net margin of 4.19% and a trailing twelve-month return on equity of 4.06%. What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.95%), Allspring Global Investments Holdings LLC (0.52%), Assenagon Asset Management S.A. (0.22%), Scout Investments Inc. (0.17%), DNB Asset Management AS (0.09%) and Peregrine Capital Management LLC (0.07%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $108.80. How much money does Neurocrine Biosciences make? Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $10.46 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.57 on an earnings per share basis. How many employees does Neurocrine Biosciences have? The company employs 900 workers across the globe. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602. This page (NASDAQ:NBIX) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.